Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
| Revenue (TTM) | $102.94M |
| Gross Profit (TTM) | $84.93M |
| EBITDA | $-15.01M |
| Operating Margin | -20.00% |
| Return on Equity | -540.00% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $11.59 |
| Book Value | $0.87 |
| Price-to-Book | 33.80 |
| Price-to-Sales (TTM) | 2.98 |
| EV/Revenue | 3.408 |
| EV/EBITDA | -2.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.20% |
| Shares Outstanding | $10.55M |
| Float | $4.98M |
| % Insiders | 40.13% |
| % Institutions | 41.41% |
Volatility is currently contracting
Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:
Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The consensus price target hints at a 31.9% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Biodesix, Inc. (BDSX) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDSX and any ticker you trade — then tracks every position and per-strategy win rate.
